GFER — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL25900	0.53	5/20
SCHEMBL56547	1.00	4/20
SCHEMBL33852	0.64	4/20
SCHEMBL20631	0.59	4/20
SCHEMBL27816	0.41	4/20
SCHEMBL27922	0.40	4/20
Resveratrol (SCHEMBL19425)	1.00	3/20
Resveratrol (SCHEMBL19426)	1.00	3/20
Promethazine (SCHEMBL41904)	1.00	3/20
Methylpromazine (SCHEMBL18993)	0.78	3/20
Methylpromazine (SCHEMBL18994)	0.78	3/20
SCHEMBL63698	0.61	3/20
Miroprofen (SCHEMBL26767)	0.58	3/20
SCHEMBL44717	0.58	3/20
SCHEMBL34104	0.54	3/20
SCHEMBL43747	0.50	3/20
Azathioprine (SCHEMBL4278)	0.49	3/20
Azathioprine (SCHEMBL26152)	0.48	3/20
Thiamiprine (SCHEMBL4852)	0.46	3/20
SCHEMBL28761	0.40	3/20

Clinical trials — most relevant to GFER by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cysteine Supplementation in Critically Ill Neonates	PHASE2/PHASE3	UNKNOWN
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy	PHASE2	RECRUITING
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects	PHASE2	COMPLETED
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)	PHASE2	COMPLETED
Electrophilic Fatty Acid Derivatives in Asthma	PHASE1	COMPLETED
NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM	PHASE1	WITHDRAWN
GSNOR Phenotyping/GSNO Challenge in Severe Asthma	EARLY_PHASE1	COMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Thiol/Disulphide Homeostasis in Unexplained Infertility	nan	COMPLETED
External Nitric Oxide Measurement Through SNO Degradation	nan	ENROLLING_BY_INVITATION
Reactive Oxygen Species Following Aortic Valve Replacement	nan	COMPLETED
Effects of Preoperative Oral Carbohydrate Loading on Maternal Thiol-disulfide Homeostasis	nan	COMPLETED
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Glycoxidation, Arterial Biomechanics, and Target Organ Damage	nan	RECRUITING
Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients	nan	COMPLETED
Covid-19: Possible Role of Neutrophil Extracellular Traps	nan	UNKNOWN
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
Evaluation of Mitochondrial Enzyme Activity in Cesarean Section Patients	nan	UNKNOWN
Comparison of Oxidants and Antioxidants in Breastmilk Under Different Anesthesia Protocols	nan	COMPLETED
Treatment Strategy to Enhance Nrf2 Signaling in Older Adults	nan	COMPLETED
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease	nan	RECRUITING
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
Functional Investigation of Endothelial Function and Regenerative Cell Exhaustion	nan	NOT_YET_RECRUITING
Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria	nan	COMPLETED
Role of Vitamin C Infusion in Postoperative Mechanically Ventilated Neonates With Sepsis	nan	COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a GFER binder may also engage these)

Protein	Name	Similarity
P56213	—	1.000	P56213 →
Q63042	—	1.000	Q63042 →
Q8JGM4	—	0.979	Q8JGM4 →
Q5EGE1	—	0.971	Q5EGE1 →
Q76KP1	—	0.971	Q76KP1 →
H2N4I1	—	0.971	H2N4I1 →
P24853	—	0.970	P24853 →
Q8BND5	—	0.970	Q8BND5 →
Q811B1	—	0.970	Q811B1 →
O08841	—	0.969	O08841 →
G3X992	—	0.969	G3X992 →
Q80WL1	—	0.969	Q80WL1 →
Q9BYB0	—	0.969	Q9BYB0 →
P47877	—	0.969	P47877 →
B1AL88	—	0.969	B1AL88 →
O54828	—	0.968	O54828 →
Q80W04	—	0.968	Q80W04 →
QSOX1	Sulfhydryl oxidase 1	0.968	landscape →
Q6IUU3	—	0.968	Q6IUU3 →
A6QLD2	—	0.968	A6QLD2 →
D3Z8X7	—	0.967	D3Z8X7 →
Q5XHC5	—	0.967	Q5XHC5 →
Q8R2K4	—	0.967	Q8R2K4 →
KAT2B	Histone acetyltransferase KAT2B	0.967	landscape →
A4IFM1	—	0.967	A4IFM1 →
Q495M9	—	0.967	Q495M9 →
P17491	—	0.967	P17491 →
Q9JHD2	—	0.966	Q9JHD2 →
O94810	—	0.966	O94810 →
P12755	—	0.966	P12755 →